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It is not easy to define the clinical course or establish a con­
sensus in the management of a disease with a relatively low 
in cidence such as granulosa cell tumor (GCT). They represent 
less than 2% of all ovarian tumors, but account for 6% of all 
ova rian malignancies [1]. GCTs generally have indolent growth 
however the potential for malignancy makes them clinically si g­
ni ficant. Although the late recurrence might be considered a 
favorable characteristic, their unpredictable behavior, parti cularly 
for the adult type, can complicate management. Owing to 
the relative infrequency with which GCTs occur, many stud­
ies regarding the outcome and treatment are small­sized and 
retro spective, and therefore difficult to implement adequately 
powered clinical trials; however, this does not imply that 
small­scaled trials have no value at all.
In this issue of Journal of Gynecologic Oncology, Lee et al. [2] 
reported a multicenter retrospective observational data of 113 
women with GCTs. Despite its retrospective nature; this is the 
first multicenter observational study currently available in Ko­
rea. It is worthy of attention because the authors put effort to 
recruit patient data from 5 different institutions in an attempt 
to provide helpful clinical insight of the disease. The authors 
were keen to investigate both adult and juvenile types and 
also included endometrial assessment data. Endometrial 
cancer occurs in association with granulosa cell tumors in at 
least 5% of cases, and 25% to 50% are reported to be associ­
ated with endometrial hyperplasia due to the stimulation of 
endometrium by unopposed estrogen production [3,4]. In 
this study, endometrial evaluation was available in 68 patients 
(66.7%). Among them, 18 patients (17.6%) had endometrial 
abnormalities including simple and complex hyperplasia, and 
one patient had expired due to endometrial cancer recur­
rence. This finding flags up the risk of endometrial abnormali­
ties related to this disease and stresses the importance of rul­
ing out concomitant endometrial pathology. 
Another acknowledgeable finding presented in this study is 
the follow­up data of subsequent pregnancies. Fertility spar­
ing surgery with unilateral salpingo­oophorectomy can be 
a reasonable approach for early stage GCT patients wishing 
to preserve their fertility. However, publications addressing 
the subsequent pregnancy outcomes after a conservative 
surgery are scarce [5,6]. This may be mainly due to the lim­
ited number of patients seen in any single institution over a 
short period. In a population­based study by Zanagnolo et al. 
[6], a conservative surgical treatment was performed in 23% 
of early­stage tumors, none of them recurred, and five of 11 
patients became pregnant after treatment. Although detailed 
information on the pregnancy outcome such as gestational 
weeks and mode of delivery are lacking in this study by Lee et 
al, it corresponds to the previous reports with favorable fertil­
ity outcome; 36 patients (35.5%) underwent fertility­sparing 
surgery and not only there was an insignificant difference in 
recurrence or survival compared with those who had received 
radical surgery, 8 patients became pregnant. Nonetheless, 
there are some clinicians that believe the primary treatment 
as the main determinant of relapse and survival rates. This 
reinforces the necessity for initial comprehensive surgical 
exploration and accurate staging [7]. Three patients in this 
study who received only cystectomy are of special concern 
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because despite the controversy and lack of standardization 
of the initial surgical procedure, the fact that GCTs are still tu­
mors of low grade malignancy should not be overlooked. It is 
important to remember that performing a more conservative 
surgery is under the condition of careful staging which reveals 
that the disease has not extended outside the involved ovary 
and that a concomitant uterine cancer has been excluded. 
Stage was the only prognostic factor for predicting recur­
rence in this study which finding corresponds well with the 
previous reports [5,8]. However, due to the rarity of the dis­
ease, tumor­dissemination patterns and prognostic factors are 
not well defined and are mostly based on retrospective data. 
Prognostic factors are important because the management 
of advanced or recurrent GCTs may not be as simple and 
favorable as early stage diseases. According to a study by Fo­
topoulou et al. [4], the tumor dissemination patterns differed 
significantly between primary and recu rrent patients, having 
significantly higher rates of diffuse peri toneal involvement 
and extraovarian tumor involvement of the middle and upper 
abdomen in the recurrent cases. Not surprisingly, only about 
85% of the relapsed patients could be operated without re­
sidual lesions compared to nearly 100% in all primary patients 
[4]. Again, the value of postoperative adjuvant therapy for 
high­risk patients has not been investigated by prospective 
randomized trials, which are difficult to perform because of 
the rarity of this tumor. 
Likewise, the rarity of a disease brings some special prob­
lems where there are simply not enough patients to produce 
the quantity of evidence that we might generally wish to see. 
Nevertheless, it is our task as clinicians to present the best 
evidence we can, when gold standard evidence is not obtain­
able. Although small­sized and retrospective, there are consid­
erable numbers of independent studies regarding GCTs. They 
may have differences, but they are also sufficiently similar that 
combining their results can lead to a conclusion that is clini­
cally interpretable and useful. Therefore, now might be the 
time for a pre­planned meta­analyses and more collaboration 
to launch prospective studies for a standardized treatment 
protocol of GCTs. What aspects should be consi dered to start 
a successful prospective trial? The first and the most important 
point will be patient recruitment. Not only rare in incidence, 
the interval from initial treatment to re currence is long, which 
may produce a problem in long­term patient follow­up. One­
third of recurrences present after more than five years after 
initial treatment and the longest documented time for recur­
rence in the literature was 37 years [9]. Therefore, adequate 
information of the disease including the low incidence of re­
currence should be provided through patient counseling for a 
durable trial. Secondly, in return for the altruism and trust from 
the volunteers that make clinical research possible, the re­
searchers have an obligation to conduct an ethical study and 
report it honestly. A disciplined education regarding study 
ethics and strict protocols by the Institutional Review Board 
should be encouraged. When the patients are adequately 
guided through the evidence to make proper informed deci­
sions then will the novel therapeutics and moral outcomes 
begin to unfold from the well­designed future trials.
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